Austin Round Table - November 16, 2019 image

Austin Round Table - November 16, 2019

Nov 16, 2019
09:00AM - 03:00PM CST
Thompson Conference Center at the University of Texas
Joe C Thompson Conference Center, 2405 Robert Dedman Dr, Austin, TX 78712, USA
Overview

On November 16, 2019, a Myeloma Crowd Round Table meeting was held in Austin, Texas at the Thompson Conference Center at the University of Texas featuring four myeloma experts, including:

    • William Matsui, MD, LIVESTRONG Cancer Institutes, Austin, TX
    • Craig Hofmeister, MD, MPH, Emory University, Atlanta, GA
    • Jason Melear, MD,Texas Oncology, Austin, TX
    • Aravind Ramakrishnan, MD, St. David’s Health Care, Austin, TX

 

Thanks to our Platinum Sponsor

User uploaded media

Thanks to our additional Myeloma Crowd Round Table Sponsors: Takeda Oncology, GSK, Celgene, Karyopharm and Adaptive Biotechnologies

 

Highlights
Speakers & Moderators
Healthtree contact William Matsui, MD

William Matsui, MD

William Matsui, MD, is Deputy Director of the LIVESTRONG Cancer Institutes, Professor in the Department Oncology and Director of Hematological Malignancies Program at the Dell Medical School at the University of Texas at Austin. He specializes in caring for patients with cancers that involve the blood and bone marrow as well as bone marrow transplantation. He came to Austin from the Johns Hopkins University School of Medicine, where he was a professor of oncology and served as the director of the Multiple Myeloma Program and the co-director of the Division of Hematologic Malignancies. Dr. Matsui has carried out laboratory-based translational research throughout his career and focused on studying cancer stem cells, tumor cells with enhanced growth potential and their role in clinical oncology. His laboratory first identified cancer stem cells in the plasma cell malignancy multiple myeloma in 2003 and subsequently in other cancers including lymphomas, leukemias and pancreas cancer. His laboratory has also demonstrated that several pathways regulating normal stem cells, including those involved in embryonic development, are abnormally activated in cancer stem cells. Dr. Matsui completed his residency training in internal medicine at the University of Washington in Seattle and his clinical training in medical oncology at Johns Hopkins. He earned his medical degree from the University of California at San Francisco.
Healthtree contact Craig Hofmeister

Craig Hofmeister

Craig C. Hofmeister, MD, MPH, is Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Board certified in internal medicine and hematology, Dr. Hofmeister’s practice focuses on plasma cell cancers, including plasmacytomas, multiple myeloma, AL amyloidosis, smoldering myeloma, and monoclonal gammopathies of renal significance. He started practicing with Emory Healthcare in 2018.